# Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS

> **NCT00025662** · PHASE2 · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 23 (actual)

## Conditions studied

- Graft vs Host Disease
- Myelodysplastic Syndromes
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myelomonocytic, Chronic
- Leukemia, Lymphocytic
- Lymphoma
- Lymphoma, Mantle-cell
- Lymphoma, Non-Hodgkin
- Hodgkin Disease

## Interventions

- **DRUG:** RFT5-SMPT-dgA
- **DRUG:** Isolex system

## Key facts

- **NCT ID:** NCT00025662
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-05
- **Primary completion:** 2008-02
- **Final completion:** 2008-02
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2016-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00025662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00025662, "Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00025662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*